(Boursier.com) — Sensorion a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the co-opted appointment of Dr. Federico Mingozzi as non-executive director of the Board of Directors of Sensorion , counting from today.
Federico Mingozzi, Ph.D., previously worked at Spark Therapeutics, where he served as Chief Science and Technology Officer. Federico brings more than 25 years of academic and industrial experience in gene therapy, immunology, biochemistry and molecular biology. He is known for his research in gene therapy for the treatment of different diseases and has contributed significantly to the understanding of the interactions between gene therapy vectors and the host immune system. Dr. Federico Mingozzi also helped characterize immune responses to AAV vectors and cell-mediated responses to AAV.
Federico Mingozzi has participated in numerous clinical trials targeting metabolic and neuromuscular diseases, hereditary blindness and bleeding disorders.
Before joining Spark Therapeutics, Federico Mingozzi was head of the immunology and hepatic gene transfer unit at Généthon, director of research at INSERM, the French National Institute of Health and Medical Research and director at Children’s Hospital of Philadelphia.
Federico Mingozzi holds a BS in Biology and a PhD in Biochemistry and Molecular Biology from the University of Ferrara in Italy, and an MBA from Drexel University.
Khalil Barrage, Interim Chairman of the Board of Directors of Sensorion, said: “We are delighted to welcome Federico Mingozzi as our new Director. His pioneering research, contribution and scientific successes recognized in the field of gene therapy will be extremely valuable to Sensorion.”
Dr. Federico Mingozzi, Non-Executive Director of Sensorion, said: “I look forward to joining the Sensorion Board of Directors and using my experience to contribute to the development of Sensorion, a company recognized for its pioneering research in the development of gene therapies for hearing disorders. Developing this research represents an exciting challenge.”